Xuerong Biotechnology(SZ:300511) Zheng Quan Zhi Xing·2025-09-03 11:17Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that Shanghai Xuerong Biotechnology Co., Ltd. has met the necessary legal requirements for the early redemption of its convertible bonds, known as "Xuerong Convertible Bonds" [4][14]. Group 1: Company Background and Bond Issuance - The company issued a total of 585 million yuan in convertible bonds, which were approved by the China Securities Regulatory Commission (CSRC) and listed on the Shenzhen Stock Exchange on July 24, 2020 [9][10]. - The bonds have a term of six years and were issued under the approval number CSRC License [2020] 634 [9]. Group 2: Redemption Conditions - The company has the right to redeem the bonds if the stock price exceeds 120% of the conversion price for at least 15 trading days within a 30-day period or if the remaining balance of the bonds is less than 30 million yuan [10][13]. - The conversion price has been adjusted multiple times, with the latest adjustment setting it at 4.10 yuan per share, effective from August 26, 2024 [12]. Group 3: Approval and Compliance - The board of directors approved the early redemption of the bonds on September 3, 2025, based on the stock price performance and market conditions [13][14]. - The company is required to fulfill its information disclosure obligations as per the relevant regulations following the redemption [14].